Login to Your Account



Genta, Allos Both Hurt By FDA Briefing Documents

By Kim Coghill


Monday, May 3, 2004
Two firms scheduled to go before the Oncologic Drugs Advisory panel today took painful financial hits on Friday when FDA reviewers released unfavorable comments about their respective cancer treatments. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription